Investor Relations, Videos April 18, 2024 Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device Read More
Investor Relations April 9, 2024 Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing Read More
Investor Relations April 4, 2024 Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device Read More
Investor Relations, Videos April 18, 2024 Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device Read More